FlowPath Lung Test for Lung Cancer

(BA-004 Trial)

This trial tests a new diagnostic tool called the FlowPath Lung Test, which examines sputum samples (mucus from the lungs) to detect lung cancer in high-risk individuals. The goal is to identify lung cancer in those with lung nodules (small growths) detected on a CT scan. This trial may suit current or former smokers with a lung nodule between 6 to 30 mm who are willing to provide a sputum sample. Participants should not have more than five nodules or a history of lung cancer in the past five years. As an unphased trial, this study offers a chance to contribute to innovative research that could enhance early lung cancer detection.

The trial information does not specify whether you need to stop taking your current medications. However, it mentions that participants on long-term medications for cancer prevention, like Tamoxifen, are not excluded, suggesting that some medications may be allowed.

Research shows that the FlowPath Lung Test, which analyzes sputum samples to detect lung cancer, is quite safe. In earlier studies with a similar test called CyPath® Lung, participants reported no harmful effects. The test proved accurate and easy for patients to manage, correctly identifying cancer 92% of the time (sensitivity) and accurately ruling out cancer 87% of the time (specificity). This indicates it works well without causing harm.

The FlowPath Lung Test is unique because it offers a non-invasive way to diagnose lung cancer by analyzing a sputum sample. Unlike traditional methods like biopsies or imaging scans, which can be invasive or require exposure to radiation, this test uses a simple sputum sample, making it more patient-friendly. Researchers are excited because this test could streamline the diagnostic process, catching lung cancer earlier and more efficiently, which could potentially lead to better outcomes for patients.

Research has shown that the FlowPath Lung Test, which participants in this trial will undergo, is promising for detecting lung cancer. Studies have found it has about 92% sensitivity, correctly identifying 92 out of 100 people with lung cancer. It also has 87% specificity, correctly identifying 87 out of 100 people without the disease. With an overall accuracy of 88%, the test is a strong choice for detecting cancer in high-risk patients with lung nodules. This reliability in early lung cancer detection can lead to faster treatment and better outcomes.¹²⁶⁷⁸